As Jerry said, at this point it does not matter if this was a de novo or a blast crisis. I concur completely with the transplant and if our usual thinking is correct, GVH, especially chronic GVH carries an strong element of GVL in myeloid malignancies. Normally when using a TKI post BMT, start dates are around 60 days. You do not comment on whether the GVH is being treated or not. My feeling would be that if not severe, allow to flare for a period of time. TKIs do interact with some of the GVH meds such as steroid and there is a potential issue there. Also TKIs may have anti-GVH effects. Dasatinib was originally developed as an immunosuppressant and imatinib has been studied in chronic GVHD. Personally, I would settle down the GVH after a flare, and initiate the TKI when the patient is nearly off immunosuppression. How long to continue is an undefined concept, but most of us would treat for a minimum of 2 years. Normally I choose the TKI that was used to get the patient to the allograft and have found imatinib, dasatinib and ponatinib safe in these situations. You may find that the patient does not tolerate a full dose of the TKI.